Sophie Streeton, PhD’s Post

Do you need robust clinical and economic evidence for the US market? What are payers really looking for? Bob Nordyke (Senior Advisor in US Evidence and HEOR – Petauri) sheds light on this critical question. Whilst US commercial payers don't specify clinical and economic evidence comparisons in the systemic way HTA markets do, strong head-to-head studies can still significantly boost your market access success. Beyond that, Bob emphasises how evidence types that are often overlooked in HTA markets can be used to effect in the US, such as: ✅ Patient-reported outcomes ✅ Patient preference information 🎥 Catch the full webinar (first broadcast in October 2024) to learn how to align your evidence portfolio with US payer expectations: https://lnkd.in/eAcuxbRE 💬 Have questions or need support with your US evidence strategy? Contact our experts at info@mtechaccess.co.uk #GlobalWhispers #USpayerevidence #marketaccess #pharma #medtech #clinicalevidence #patientoutcomes #patientpreferences #patientchoice

Do you need robust clinical and economic evidence for the US market? What are payers really looking for? Bob Nordyke (Senior Advisor in US Evidence and HEOR – Petauri) sheds light on this critical question. Whilst US commercial payers don't specify clinical and economic evidence comparisons in the systemic way HTA markets do, strong head-to-head studies can still significantly boost your market access success. Beyond that, Bob emphasises how evidence types that are often overlooked in HTA markets can be used to effect in the US, such as: ✅ Patient-reported outcomes ✅ Patient preference information 🎥 Catch the full webinar (first broadcast in October 2024) to learn how to align your evidence portfolio with US payer expectations: https://lnkd.in/eyFVQpMb 💬 Have questions or need support with your US evidence strategy? Contact our experts at info@mtechaccess.co.uk #GlobalWhispers #USpayerevidence #marketaccess #pharma #medtech #clinicalevidence #patientoutcomes #patientpreferences #patientchoice

Do you need robust clinical and economic evidence for the US market? What are payers really looking for? Bob Nordyke (Senior Advisor in US Evidence and HEOR – Petauri) sheds light on this critical question. Whilst US commercial payers don't specify clinical and economic evidence comparisons in the systemic way HTA markets do, strong head-to-head studies can still significantly boost your market access success. Beyond that, Bob emphasises how evidence types that are often overlooked in HTA markets can be used to effect in the US, such as: ✅ Patient-reported outcomes ✅ Patient preference information 🎥 Catch the full webinar (first broadcast in October 2024) to learn how to align your evidence portfolio with US payer expectations: https://lnkd.in/ePvNjAJJ 💬 Have questions or need support with your US evidence strategy? Contact our experts at info@mtechaccess.co.uk #GlobalWhispers #USpayerevidence #marketaccess #pharma #medtech #clinicalevidence #patientoutcomes #patientpreferences #patientchoice

Do you need robust clinical and economic evidence for the US market? What are payers really looking for? Bob Nordyke (Senior Advisor in US Evidence and HEOR – Petauri) sheds light on this critical question. Whilst US commercial payers don't specify clinical and economic evidence comparisons in the systemic way HTA markets do, strong head-to-head studies can still significantly boost your market access success. Beyond that, Bob emphasises how evidence types that are often overlooked in HTA markets can be used to effect in the US, such as: ✅ Patient-reported outcomes ✅ Patient preference information 🎥 Catch the full webinar (first broadcast in October 2024) to learn how to align your evidence portfolio with US payer expectations: https://lnkd.in/eC6u4u3d 💬 Have questions or need support with your US evidence strategy? Contact our experts at info@mtechaccess.co.uk #GlobalWhispers #USpayerevidence #marketaccess #pharma #medtech #clinicalevidence #patientoutcomes #patientpreferences #patientchoice

The importance of real-world evidence (RWE) and patient-reported outcomes (PROs) cannot be understated in demonstrating the true value of new therapies. HTA bodies, such as NICE in the UK, increasingly demand this type of evidence, recognising that clinical trial data is not the full story. At Bioscript Group, we understand that successful market access requires a proactive, collaborative approach that integrates RWE and PROs into your strategy from the earliest stages of development. 🤝Early engagement is key: By involving market access experts alongside medical affairs from the outset, we can ensure that your clinical trials are designed to generate the evidence payers need to make informed decisions. 📊Data-driven insights: Our team of senior scientists leverages RWE and PROs to build a compelling, patient-centric case for your therapy, showcasing its real-world effectiveness and value. 🗣️Strategic storytelling: We translate complex data into clear, impactful narratives that resonate with payers and HTA bodies. We're not just a service provider; we're your strategic partner in ensuring your innovative therapies reach those who need them most #MarketAccess #HealthcareCommunications #Pharma Valid Insight (part of the Bioscript Group)

Implications of inadequate evidence are often not fully understood. Missing or incomplete data at launch can lead to limited reimbursement, restricted patient access, and impact commercial success. Market Access teams must ensure they create and disseminate a cross-functional understanding of payers' and HTA bodies' evidence needs, the types of evidence required, and how this data will be viewed and interpreted. Read on for insights and key success levers in the Market Access Excellence Framework. https://lnkd.in/dibbv-AA #Pharma #BusinessSuccess #Business

Catch up on last month's key industry news with The Evidence Base® June 2024 Round-up. Including news from the European Union, Clarivate, HealthWise Data, NICE - National Institute for Health and Care Excellence, THREAD, SEQSTER, Parexel, , ISPOR—The Professional Society for Health Economics and Outcomes Research, HealthVerity and the FDA. #heor #healtheconomics #outcomesresearch #rwe #rwd #realworldevidence #realworlddata #marketaccess #pharma #biopharma #medicalaffairs #regulation #regulatoryaffairs #hta #healthtechnologyassessment #healthdata #healthequity #healthpolicy

Implications of inadequate evidence are often not fully understood. Missing or incomplete data at launch can lead to limited reimbursement, restricted patient access, and impact commercial success. Market Access teams must ensure they create and disseminate a cross-functional understanding of payers' and HTA bodies' evidence needs, the types of evidence required, and how this data will be viewed and interpreted. Read on for insights and key success levers in the Market Access Excellence Framework. https://lnkd.in/dh8fQzcG #Pharma #BusinessSuccess #Business

𝟭𝟬 𝗔𝗽𝗿𝗶𝗹 📅 𝐒𝐀𝐕𝐄 𝐓𝐇𝐄 𝐃𝐀𝐓𝐄📅 #BeneathTheSurface 🌊 : Unravelling the True Value of Generic Medicines our upcoming study unravelling the long-term benefits of #GenericMedicines to ensure sustainability and availability of essential medicines 💊   Deep dive into this topic during our online panel and discover all the societal and economic values that generic medicines bring to the healthcare sector and society as a whole – register now and do not miss all the updates! https://lnkd.in/dxfHgEwp

CIOMS is pleased to announce the publication of the consensus report on Real-World Data and Real-World Evidence in Regulatory Decision Making, addressing the use of RWE for regulatory and healthcare decisions. #realworlddata #RWE #RWD #healthcare #regulatoryscience #CIOMS #medicalaffairs #medicinesdevelopment #GMDPacademy